PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway.
Hodgins JJ, Abou-Hamad J, O'Dwyer CE, Hagerman A, Yakubovich E, Tanese de Souza C, Marotel M, Buchler A, Fadel S, Park MM, Fong-McMaster C, Crupi MF, Makinson OJ, Kurdieh R, Rezaei R, Dhillon HS, Ilkow CS, Bell JC, Harper ME, Rotstein BH, Auer RC, Vanderhyden BC, Sabourin LA, Bourgeois-Daigneault MC, Cook DP, Ardolino M.
Hodgins JJ, et al. Among authors: vanderhyden bc.
J Exp Med. 2024 Jul 1;221(7):e20221721. doi: 10.1084/jem.20221721. Epub 2024 Jun 13.
J Exp Med. 2024.
PMID: 38869480